Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 1013-1021. doi: 10.19723/j.issn.1671-167X.2023.06.009

Previous Articles     Next Articles

Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis

Xue ZOU1,2,Xiao-juan BAI1,Li-qing ZHANG1,*()   

  1. 1. Department of Rheumatology and Immunology, Fenyang Hospital Affiliated to Shanxi Medical University, Shanxi Province Fenyang Hospital, Fenyang 032200, Shanxi, China
    2. Department of Gastroenterology, Suzhou Yongding Hospital, Suzhou 215100, Jiangsu, China
  • Received:2023-08-24 Online:2023-12-18 Published:2023-12-11
  • Contact: Li-qing ZHANG E-mail:zhanglq828@sohu.com
  • Supported by:
    the Key Science and Technology Program of Shanxi Province Fenyang Hospital(2021-2022-03)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the efficacy and safety of iguratimod combined with tofacitinib in patients with difficult-to-treat moderate-to-severe rheumatoid arthritis (RA). Methods: In this prospective clinical study, 30 patients with difficult-to-treat moderate-to-severe RA who attended the Department of Rheumatology and Immunology of Shanxi Province Fenyang Hospital from September 2021 to June 2022 were selected. Twenty-three patients enrollment had been treated with 2 or more conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) for more than 6 months. At least, methotrexate or leflunomide was included. Seven patients were treated with conventional synthetic DMARDs combined with tumor necrosis factor antagonists. Because all the patients had not reached the target of treatment, the combination treatment regimen of DMARDs was changed to iguratimod and tofacitinib. The observation period was 12 weeks. Clinical data were collected before and after treatment. At the end of 4 weeks, 8 weeks and 12 weeks, the clinical data were collected such as swollen joints count (SJC), tender joints count (TJC), time of morning stiffness, clinical disease activity index (CDAI), health status assessment questionnaire (HAQ), and 28-joint disease activity score (DAS28) were included. We collected laboratory indicators, recorded the patient's medication, and observed some changes to see if any adverse drug reactions occurred during the treatment. Results: There were significant differences in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), platelet (PLT), SJC, TJC, DAS28 based on ESR(DAS28-ESR), time of morning stiffness, HAQ, CDAI, and anti-cyclic citrullinated peptide antibody before and after treatment. The differences had statistical significance (P < 0.05). There was no statistical differences in globulin before and after treatment (P>0.05). During the treatment of iguratimod combined with tofacitinib, there was no serious adverse reactions such as leukopenia, significant elevation of liver enzymes, allergy or thromboemblolic events that occurred in all the patients. Conclusion: Iguratimod combined with tofacitinib in the treatment of difficult-to-treat moderate-to-severe RA may have efficacy. The machanism was improving the patients' recent clinical symptoms by reducing inflammatory indexes. This combination treatment regimen with iguratimod and tofacitinib has a good safety profile.

Key words: Rheumatoid arthritis, Iguratimod, Tofacitinib, Treatment outcome, Safety

CLC Number: 

  • R593.22

Table 1

Pharmacy of patients before enrollment (n=30)"

Usage of drugs n (%)
Two csDMARDs 21 (70.00)
    MTX and HCQ 6 (20.00)
    MTX and SSZ 9 (30.00)
    MTX and IGU 3 (10.00)
    LEF and IGU 2 (6.67)
    LEF and HCQ 1 (3.33)
Three csDMARDs 2 (6.66)
    MTX, HCQ and SSZ 1 (3.33)
    LEF, HCQ and SSZ 1 (3.33)
csDMARDs and bDMARDs 7 (23.34)
    MTX and etanercept 3 (10.00)
    MTX and adalimumab 1 (3.33)
    LEF and etanercept 2 (6.64)
LEF and adalimumab 1 (3.33)
Prednisone (≤10 mg/d) 22 (73.33)
NSAIDs 18 (60.00)

Table 2

Comparison of disease activity indicators before and after treatment (n=30)"

Project Before treatment, M (P25, P75) After treatment, M (P25, P75) Wald χ2 P
4 weeks 8 weeks 12 weeks
ESR/(mm/h) 60.00 (42.75, 82.75) 30.05 (16.5, 53.00) 17.50 (10.05, 30.50) 9.00 (4.25, 13.50) 134.183 <0.001*
CRP/(mg/L) 22.97 (11.81, 43.89) 6.94 (2.20, 15.86) 3.45 (1.03, 6.41) 1.30 (0.33, 3.10) 37.586 <0.001*
RF/(IU/mL) 82.30 (22.43, 308.70) 53.00 (19.38, 202.50) 39.50 (13.40, 111.63) 18.50 (7.23, 59.83) 15.759 0.001*
PLT/(×109/L) 316.50 (234.50, 394.50) 250.50 (210.50, 308.00) 242.50 (213.00, 283.00) 242.00 (213.00, 313.50) 19.278 <0.001*
Globulin/(g/L) 31.60 (25.42, 34.02) 28.05 (24.72, 33.05) 27.30 (23.62, 32.55) 5.648 0.130
DAS28-ESR 4.77 (4.13, 5.60) 3.67 (2.75, 4.10) 1.83 (1.08, 2.94) 1.14 (0.72, 2.62) 393.417 <0.001*
Morning stiffness/min 90.00 (57.50, 120.00) 52.50 (27.50, 120.00) 20.00 (10.00, 41.25) 5.00 (0.00, 16.25) 122.857 <0.001*
SJC 8.50 (5.75, 12.00) 5.00 (2.00, 8.00) 2.50 (1.00, 4.00) 1.00 (0.00, 3.00) 129.482 <0.001*
TJC 9.51 (6.00, 14.25) 7.00 (4.00, 10.00) 3.00 (2.00, 6.00) 2.00 (2.00, 5.50) 153.105 <0.001*
CDAI 32.00 (22.75, 43.00) 24.00 (13.50, 28.00) 9.50 (5.00, 15.00) 5.00 (1.75, 9.75) 211.187 <0.001*
HAQ 10.00 (7.00, 17.00) 6.50 (4.00, 10.00) 5.00 (2.75, 7.25) 2.00 (1.75, 9.75) 141.037 <0.001*
ACPA/(IU/mL) 246.00 (153.75, 294.75) 138.00 (106.50, 232.50) 56.986 <0.001*

Table 3

Comparison of disease activity indicators before and after treatment (generalized estimation equation model analysis and multiple comparisons of time effects based on the before treatment group)"

Project Group β(95%CI) Wald χ2 P
ESR Before treatment
4 weeks -27.867 (-36.365, -19.368) 41.302 <0.001*
8 weeks -40.433 (-49.870, -30.997) 70.524 <0.001*
12 weeks -50.600 (-59.823, -41.377) 115.614 <0.001*
CRP Before treatment
4 weeks -24.367 (-36.299, -12.435) 16.020 <0.001*
8 weeks -30.088 (-42.632, -17.543) 22.100 <0.001*
12 weeks -32.867 (-45.684, -20.049) 25.257 <0.001*
RF Before treatment
4 weeks -42.168 (-69.685, -14.652) 9.022 0.003*
8 weeks -86.759 (-131.934, -41.584) 14.169 <0.001*
12 weeks -139.566 (-222.283, -56.849) 10.936 0.001*
PLT Before treatment
4 weeks -49.900 (-79.813, -19.987) 10.690 <0.001*
8 weeks -56.833 (-83.675, -29.991) 17.221 <0.001*
12 weeks -60.933 (-88.237, -33.630) 19.132 <0.001*
SJC Before treatment
4 weeks -3.733 (-4.595, -2.872) 72.147 <0.001*
8 weeks -6.567 (-7.701, -5.433) 128.777 <0.001*
12 weeks -7.833 (-9.219, -6.447) -15.346 <0.001*
TJC Before treatment
4 weeks -4.000 (-5.205, -2.795) 42.353 <0.001*
8 weeks -6.700 (-8.216, -5.184) 75.053 <0.001*
12 weeks -8.933 (-10.429, -7.438) 137.104 <0.001*
DAS28-ESR Before treatment
4 weeks -1.286 (-1.553, -1.020) 89.469 <0.001*
8 weeks -2.893 (-3.228, -2.557) 285.404 <0.001*
12 weeks -3.459 (-3.801, -3.117) 392.627 <0.001*
Morning stiffness Before treatment
4 weeks -21.000 (-29.333, -12.667) 24.395 <0.001*
8 weeks -57.267 (-68.908, -45.625) 92.962 <0.001*
12 weeks -73.833 (-87.535, -60.132) 111.545 <0.001*
HAQ Before treatment
4 weeks -4.300 (-5.201, -3.399) 87.446 <0.001*
8 weeks -6.700 (-7.877, -5.523) 124.579 <0.001*
12 weeks -8.900 (-10.394, -7.406) 136.386 <0.001*
CDAI Before treatment
4 weeks -11.217 (-13.516, -8.917) 91.402 <0.001*
8 weeks -21.650 (-25.044, -18.256) 156.323 <0.001*
12 weeks -26.350 (-30.079, -22.621) 191.827 <0.001*
ACPA Before treatment
After treatment -68.267 (-85.991, -50.542) 56.986 <0.001*

Table 4

Comparison of disease activity composition ratio before and after treatment (n=30)"

Items Remission, n (%) Low disease activity, n (%) Moderate disease activity, n (%) High disease activity, n (%) Z P
Before treatment 0 (0) 0 (0) 16 (53.33) 14 (46.67)
4 weeks 7 (23.33) 3 (10.00) 15 (50.00) 5 (16.67) -3.491 <0.05*
8 weeks 15 (50.00) 10 (33.33) 3 (10.00) 2 (6.67) -5.828 <0.05*
12 weeks 21 (70.00) 7 (23.33) 2 (6.67) 0 (0) -6.704 <0.05*

Table 5

Comparison of disease activity indicators at 4, 8 and 12 weeks after treatment and before treatment (t test)"

Items ESR CRP RF PLT DAS28-ESR Morning stiffness SJC TJC CDAI HAQ ACPA
4 weeks t -7.51 -5.23 -1.54 -4.18 -8.16 -3.81 -7.31 -6.61 -8.10 -8.58
P <0.05* <0.05* 0.12 <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05*
8 weeks t -10.91 -6.46 0.002 -4.77 -18.35 -10.40 -12.86 -11.08 -15.64 -15.64
P <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05*
12 weeks t -13.65 -7.06 -5.12 -5.11 -21.95 -12.86 -15.34 -14.77 -19.04 -19.04 -7.42
P <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05* <0.05*

Figure 1

Comparison of DAS28-ESR composition ratio before and after treatment (n=30) DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate."

Table 6

Comparison of routine laboratory indicators before and after treatment (n=30)"

Project Before treatment, M (P25, P75) After treatment, M (P25, P75) Wald χ2 P
4 weeks 8 weeks 12 weeks
WBC/(×109/L) 7.35 (6.48, 8.84) 6.74 (5.57, 7.90) 6.39 (5.08, 7.73) 6.07 (5.43, 7.56) 5.090 0.165
RBC/(×1012/L) 4.27 (4.09, 4.67) 4.40 (4.17, 4.65) 4.51 (4.25, 4.90) 4.49 (4.26, 4.83) 15.936 0.001*
HGB/(g/L) 125.50 (111.75, 137.25) 122.00 (114.75, 129.25) 126.50 (114.75, 142.50) 132.00 (121.00, 141.75) 10.300 0.016*
ALT/(U/L) 17.00 (15.00, 27.00) 18.50 (14.00, 23.25) 17.00 (15.00, 24.00) 18.50 (15.75, 25.75) 9.138 0.028*
AST/(U/L) 18.50 (15.00, 25.25) 18.50 (14.00, 23.00) 19.50 (15.00, 24.00) 18.50 (15.00, 28.00) 1.905 0.592
GGT/(U/L) 19.00 (14.00, 31.50) 18.00 (14.75, 22.50) 15.50 (12.75, 23.50) 15.00 (12.00, 22.50) 2.727 0.436
Total protein/(g/L) 74.00 (71.87, 76.62) 76.00 (69.20, 77.85) 73.25 (70.75, 77.47) 73.30 (70.00, 82.22) 2.417 0.490
Albumin/(g/L) 43.95 (41.60, 46.15) 44.70 (42.92, 47.35) 45.55 (42.77, 47.52) 45.65 (43.30, 47.45) 5.845 0.119
Cr/(μmol/L) 62.50 (56.75, 72.50) 65.00 (59.00, 76.30) 67.00 (56.75, 73.50) 66.00 (58.75, 77.00) 5.149 0.161
BUN/(mmol/L) 4.40 (3.70, 5.02) 4.60 (4.20, 5.45) 4.70 (4.40, 6.10) 4.65 (4.37, 5.32) 8.214 0.042*

Table 7

Comparison of routine testing indicators before and after treatment (n=30)"

Project Group β(95%CI) Wald χ2 P
RBC Before treatment
4 weeks 0.369 (0.022, 0.717) 4.334 0.037*
8 weeks 0.261 (0.063, 0.460) 6.674 0.010*
12 weeks 0.532 (0.234, 0.831) 12.227 <0.001*
HGB Before treatment
4 weeks -2.433 (-9.203, 4.336) 0.496 0.481
8 weeks 2.300 (-3.816, 8.416) 0.543 0.461
12 weeks 6.500 (-1.942, 14.942) 2.277 0.131
ALT Before treatment
4 weeks -4.933 (-8.176, -1.690) 8.890 0.003*
8 weeks -3.633 (-7.479, 0.212) 3.429 0.064*
12 weeks -2.333 (-6.553, 1.886) 1.175 0.278
BUN Before treatment
4 weeks 0.297 (-0.124, 0.717) 1.911 0.167
8 weeks 4.237 (-0.886, 9.359) 2.628 0.105
12 weeks 0.360 (0.037, 0.683) 4.766 0.029*
1 Smolen JS , Landewé RBM , Bijlsma JWJ , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2020, 79 (6): 685- 699.
doi: 10.1136/annrheumdis-2019-216655
2 de Hair MJH , Jacobs JWG , Schoneveld JLM , et al. Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need[J]. Rheumatology (Oxford), 2018, 57 (7): 1135- 1144.
3 Buch MH . Defining refractory rheumatoid arthritis[J]. Ann Rheum Dis, 2018, 77 (7): 966- 969.
doi: 10.1136/annrheumdis-2017-212862
4 Smolen JS , Aletaha D , Mcinnes IB . Rheumatoid arthritis[J]. Lancet, 2016, 388 (10055): 2023- 2038.
doi: 10.1016/S0140-6736(16)30173-8
5 Aletaha D , Neogi T , Silman AJ , et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative initiative[J]. Arthritis Rheum, 2010, 62 (9): 2569- 2581.
doi: 10.1002/art.27584
6 Wu D , Luo Y , Li T , et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment[J]. Front Immunol, 2022, 13, 1051082.
doi: 10.3389/fimmu.2022.1051082
7 Sun X , Li R , Cai Y , et al. Clinical remission of rheumatoid arthritis in a multi center real-world study in Asia-Pacific region[J]. Lancet Reg Health West Pac, 2021, 15, 100240.
doi: 10.1016/j.lanwpc.2021.100240
8 李宏超, 徐丽玲, 苏茵. 难治性类风湿关节炎诊治探讨[J]. 中华风湿病学杂志, 2019, 23 (10): 689- 693.
9 Nagy G , Roodenrijs NMT , Welsing PM , et al. EULAR definition of difficult-to-treat rheumatoid arthritis[J]. Ann Rheum Dis, 2021, 80 (1): 31- 35.
doi: 10.1136/annrheumdis-2020-217344
10 Xie S , Li S , Tian J , et al. Iguratimod as a new drug for rheumatoid arthritis: Current landscape[J]. Front Pharmacol, 2020, 11, 73.
doi: 10.3389/fphar.2020.00073
11 Xu Y , Zhu Q , Song J , et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis[J]. Mediators Inflamm, 2015, 2015, 356040.
12 Wen L , Jiang W , Zhou M , et al. Effect of combined application of iguratimod in the treatment of active rheumatoid arthritis on bone metabolism, Th17 cells and Treg cells[J]. Am J Transl Res, 2021, 13 (3): 1676- 1684.
13 Liu S , Song LP , Li RB , et al. Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway[J]. World J Clin Cases, 2021, 9 (10): 2181- 2191.
doi: 10.12998/wjcc.v9.i10.2181
14 Li CH , Ma ZZ , Jian LL , et al. Iguratimod inhibits osteoclastoge-nesis by modulating the RANKL and TNF-α signaling pathways[J]. Int Immunopharmacol, 2021, 90, 107219.
doi: 10.1016/j.intimp.2020.107219
15 Kondo N , Kuroda T , Kobayashi D . Cytokine networks in the pa-thogenesis of rheumatoid arthritis[J]. Int J Mol Sci, 2021, 22 (20): 10922.
doi: 10.3390/ijms222010922
16 Malemud CJ . The role of the JAK/STAT signal pathway in rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis, 2018, 10 (5/6): 117- 127.
17 疏金玲, 张玲玲, 魏伟. 酪氨酸激酶抑制剂治疗类风湿关节炎研究进展[J]. 中国药理学与毒理学杂志, 2020, 34 (9): 713- 720.
18 Puigdevall L , Michiels C , Stewardson C , et al. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?[J]. J Cell Mol Med, 2022, 26 (7): 1865- 1875.
doi: 10.1111/jcmm.17168
19 戴冰冰, 刘佳丽, 李宁宁, 等. 托法替布治疗难治性中重度类风湿关节炎的疗效及安全性[J]. 实用临床医药杂志, 2022, 26 (11): 122- 126.
20 Zheng N , Guo C , Wu R . Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to metho-trexate-cyclosporin A-hydroxychloroquine-prednisone[J]. Scand J Rheumatol, 2018, 47 (5): 422- 424.
doi: 10.1080/03009742.2017.1376109
21 Mizutani S , Kodera H , Sato Y , et al. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis[J]. Clin Rheumatol, 2021, 40 (1): 123- 132.
doi: 10.1007/s10067-020-05208-y
22 Inoue A , Nozaki Y , Hirooka Y , et al. The effectiveness and retention rate of iguratimod in Japanese rheumatoid arthritis patients with/without methotrexate in daily medical care[J]. Life (Basel), 2020, 10 (11): 261.
23 Ouyang D , Ma YZ , Zou J , et al. Effectiveness and safety of iguratimod monotherapy or combined with methotrexate in treating rheumatoid arthritis: A aystematic review and meta-analysis[J]. Front Pharmacol, 2022, 13, 911810.
24 Smolen JS , Landewe R , Breedveld FC , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update[J]. Ann Rheum Dis, 2014, 73 (3): 492- 509.
25 Angelini J , Talotta R , Roncato R , et al. JAK-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future[J]. Biomolecules, 2020, 10 (7): 1002.
26 张春燕, 范小冬, 秦元, 等. JAK抑制剂托法替布治疗类风湿性关节炎效果的Meta分析[J]. 第三军医大学学报, 2018, 40 (6): 543- 550.
27 Sands BE , Taub PR , Armuzzi A , et al. Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2020, 18 (1): 123- 132.e3.
28 Taylor PC , Kremer JM , Emery P , et al. Lipid profile and effect of statin treatment in pooled phase Ⅱ and phase Ⅲ baricitinib studies[J]. Ann Rheum Dis, 2018, 77 (7): 988- 995.
[1] Zhaode BU, Mengyu FENG, Ke JI. Practice and reflection on sentinel lymph node navigation surgery for early gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 239-243.
[2] Youdong LIU, Yajun LYU, Jie CHEN, Mingde ZANG, Hongda PAN, Xiaowen LIU, Jun LU, Fenglin LIU. Clinical efficacy and safety of totally laparoscopic subtotal gastrectomy with cardia-gastric fundus preservation in middle-upper gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 301-306.
[3] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[4] Weihao LI, Xuemin ZHANG, Wei LI, Tao ZHANG, Xiaoming ZHANG. Outcomes of suture-mediated vascular closure device in the closure of left brachial artery access site after thoracic endovascular aortic repair [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 388-392.
[5] Ebrahimi Farin, Zhiqiang FENG, Ebrahimi Faraz, Weihua HAN, Ziyang YU, Kuankuan JIA, Jingang AN. Surgical treatment outcomes of different stages of maxillary medication-related osteonecrosis of the jaw [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 107-114.
[6] Lianfei PAN, Wenjing LI, Ruiyang WANG, Jian JIAO, Zhanqiang CAO, Li GAO, Dong SHI. Short-term efficacy and influencing factors of systemic antibiotics as an adjunct to mechanical periodontal therapy for stages Ⅲ/Ⅳ periodontitis [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 30-36.
[7] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[8] Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207.
[9] Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918.
[10] Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925.
[11] Yuanyuan YANG, Shanshan ZHANG, Guangyan YU, Huijun YANG, Hongyu YANG. Clinical outcomes of partial sialoadenectomy for the treatment of benign tumors in the submandibular gland [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 334-339.
[12] Yifan KANG, Yanjun GE, Xiaoming LV, Shang XIE, Xiaofeng SHAN, Zhigang CAI. One-stage mandibular reconstruction combining iliac flap with immediate implant-based denture [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 78-84.
[13] Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016.
[14] Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114.
[15] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd